CVS/Caremark settles with states
Firm settles multi-state consumer protection investigation into PBM practices, including therapeutic switching by its legacy AdvancePCS and Caremark subsidiaries by agreeing to payments of up to $41 million. Led by the Illinois and Maryland attorneys general, the investigation by a total of 28 states began in 2004. Of the total payment amount, $38.5 million will go to the states and up to $2.5 million will be allocated to patients who had to undergo medical tests related to switches of cholesterol-reducing drugs. A consent order also restricts therapeutic interchanges by the PBM and requires greater transparency from the company regarding its incentives for switches. CVS/Caremark maintains the agreement involves no admission of wrongdoing on its part. The firm settled federal charges against its legacy subsidiaries in 2005 (1"The Pink Sheet," Sept. 12, 2005, p. 13)...
You may also be interested in...
Caremark's focus on resolving allegations of kickbacks and false claims related to its AdvancePCS subsidiary is expected to shift to state investigations following a $137.5 mil. settlement with federal prosecutors
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
“When COVID-19 hit, we really decided to accelerate plans,” says BlueWillow CEO Dave Peralta. NanoBio Protect contains OTC monograph ingredient benzalkonium chloride in a proprietary nanotechnology, alcohol-free formulation to help reduce germs on skin inside and around the nose that could cause infections.